Chief Executive Officer
Emma joined Isogenica as Chief Executive Officer in September 2018. She is passionate about technologies that can accelerate drug discovery and development, and experienced in leading highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing sustainable businesses.
Director of Commercial Development
Adam joined Isogenica in May 2015. He brings wide-ranging expertise in the pharmaceutical and biotech industry from senior business development positions at Ablynx nv, Astrazeneca-Medimmune PLC, Leiden University and Horizon Discovery Ltd, where he was Founder Business Development Director.